Lurosetron

Lurosetron (INN) is a serotonin 5-HT3 receptor antagonist.[1]

Lurosetron
Clinical data
ATC code
  • none
Identifiers
  • 6-fluoro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H17FN4O
Molar mass312.348 g·mol−1
3D model (JSmol)
  • CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=C(N3C)C(=CC=C4)F
  • InChI=1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20) N
  • Key:NUMKWGDDRWJQMY-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

Synthesis

References

  1. Prakash SP, Cable KM, Correa ID, Fellows L, Montgomery S, Newman JJ, Waterhouse L, Wells GN, Sutherland DR (1995). "Synthesis of isotopically labelled pyridoindolone 5-HT3 receptor antagonists". Journal of Labelled Compounds and Radiopharmaceuticals. 36 (10): 993–1007. doi:10.1002/jlcr.2580361011.
  2. EP 0353983, Coates, Ian Harold; Oxford, Alexander William & North, Peter Charles et al., published 1990-02-07, assigned to Glaxo Group Ltd.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.